CONTEXT: European politics aside (and there are so many wheels within wheels on that one!) there are many RWR / RWE topics exposed in this opinion piece. Not least of which the way RWR can influence for the better, early stage research and of note for all of us in the field, the prediction of accelerated changes in the regulatory framework and how data is collected
IMPACT: High
READ TIME: 5 mins
Quality Level Mean [1 – 10]: 9
1. “Health systems generate mountains of data, but it’s not always formatted in a way that’s easily accessible for the researchers who need it ”
2. ” Angela Weiss/AFP via Getty Images. This article is the product of a POLITICO Working Group.”
3. “This isn’t the first time pharmaceutical companies stumbled in the design of clinical trials, says Tit Albreht, head of the Centre for Health Care at Slovenia’s National Institute of Public Health.”
4. “Even in a successful Phase 2 drug study, a medicine might have something like a 30 percent positive response, so “we have 70 percent of the patients in the studies that are left out without any responses,” said Andrej-Franc Plesničar, senior adviser at the Health Insurance Institute of Slovenia, at the POLITICO roundtable.”
5. “According to John Ryan, DG SANTE’s director for public health, cancer registries — depositories of patient data concerning the disease — “need to be substantially improved.””
Source URL: https://www.politico.eu/article/coronavirus-rethink-how-we-study-drugs/